Oil Is the New Gold
Health Care: Drugs
DARA Biosciences Inc. (DARA: NASDAQ)
$0.67 -0.02 | -2.88%
06/19/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -7.74M | -6.48M | -5.99M | -3.56M |
| Operating Gains/Losses | -608.60K | 1.51K | 160.00 | -1.21M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -173.38K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | -125.28K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 966.65K | 291.08K | -24.82K | -491.52K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | -347.29K | 256.82K | -54.42K |
| (Increase) Decrease In Other Working Capital | 0.00 | -279.72K | 11.10K | 15.45K |
| Other Non-Cash Items | 1.08M | 1.67M | 628.02K | 692.52K |
| Net Cash From Continuing Operations | -7.02M | -4.86M | -5.11M | -4.42M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -7.02M | -4.86M | -5.11M | -4.42M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 350.00 | 1.05K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 178.12K |
| Purchases of Property, Plant & Equipment | -268.06K | 0.00 | -6.85K | -4.00K |
| Acquisitions | -19.29K | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 746.70K | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 459.35K | 0.00 | -6.50K | 675.18K |
| Issuance of Debt | 0.00 | 114.77K | 121.52K | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.17M | 562.50K | 100.00K | 5.47M |
| Repayment of Long-Term Debt | 0.00 | -115.35K | -130.88K | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 10.71M | -370.00 | 7.34M | 486.51K |
| Net Cash From Financing Activities | 11.88M | 561.55K | 7.43M | 5.95M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 5.32M | -4.30M | 2.31M | 2.21M |
Portfolios with DARA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserStan/Gino
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserIf you can't join them,whup...
- Usergarym
Latest DARA Headlines from TheStreet
- 5 Stocks Under $10 Poised to Pop 01.24.13 | 12:01 pm
- 5 Stocks Under $10 Set to Soar Higher 09.27.12 | 01:09 pm
- 3 Stocks Under $5 Moving Higher 09.13.12 | 02:09 pm
- 5 Stocks Under $10 Set to Soar Higher 08.30.12 | 12:08 pm
- Report From Results Of A Successful Phase II Study For DARA's KRN5500 At ADEPT 03.29.11 | 08:03 am
- DARA BioSciences Filing Shelf Registration Statement To Replace Expiring Registration Statement 03.25.11 | 04:03 pm
- DARA BioSciences Is Selected By MDB Capital Group As A 2011 "Best & Brightest-Company To Watch" 02.23.11 | 08:02 am
- DARA BioSciences To Present At The Wall Street Analyst Forum 22nd Annual Analyst Conference 02.17.11 | 09:02 am
- Agile Companies Like DARA BioSciences Advance Research For New Diabetes Medicines As Incidence Of Disease Relentlessly Increases 02.15.11 | 09:02 am
- Study Results For DARA Biosciences' Lead Drug For Neuropathic Pain, KRN5500, Selected For Presentation By The International Conference On Accelerating The Development Of Enhanced Pain Treatments ("ADEPT") 02.01.11 | 08:02 am
Press Releases for DARA
- DARA BioSciences Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule - Business Wire 02.14.13 | 08:02 am
- DARA BioSciences To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.11.13 | 08:02 am
- DARA BioSciences To Present At The 6th Annual OneMedForum Conference - Business Wire 01.08.13 | 08:01 am
- DARA BioSciences To Raise $2.8 Million Pursuant To Securities Purchase Agreement - Business Wire 12.31.12 | 08:12 am
- DARA BioSciences Announces Submission Of KRN5500 To FDA For Orphan Designation - Business Wire 11.29.12 | 08:11 am
- Dara Biosciences Reports Financial Results For The Third Quarter 2012 - Business Wire 11.14.12 | 05:11 pm
- DARA BioSciences Will Present At NYSSA Investing In Life Sciences Conference, November 29 - Business Wire 11.12.12 | 09:11 am
- DARA BioSciences Will Present At Singular Research Conference November 1 - Business Wire 10.29.12 | 03:10 pm
- Soltamox, Liquid Version Of Tamoxifen Citrate (Photo: Business Wire) - Business Wire 10.22.12 | 06:10 am
- Soltamox, Liquid Version Of Tamoxifen Citrate (Photo: Business Wire) - Business Wire 10.22.12 | 06:10 am
Partner Headlines for DARA
- Benzinga's Small Cap Movers for Friday November 16, 2012 - Benzinga 11.18.12 | 11:11 am
- Benzinga's Microcap Movers for Friday September 14, 2012 - Benzinga 09.15.12 | 08:09 pm
- DARA Biosciences Inks Deal - Analyst Blog - NASDAQ 08.23.12 | 10:08 pm
- DARA Biosciences Inks Deal - Analyst Blog - Zacks 08.23.12 | 07:08 pm
- DARA Bio Starting To Look Interesting - Analyst Blog - Zacks 05.08.12 | 10:05 am
- Morning Market Losers - Benzinga 04.09.12 | 09:04 am
- Morning Market Movers - Benzinga 03.26.12 | 09:03 am
- DARA BioSciences Spiking Higher after Positive Phase I Results - Benzinga 06.28.11 | 09:06 am
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- News Summary - Benzinga 12.29.10 | 09:12 am
